European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.
Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
EMA committee recommends approval for AbbVie’s Maviret for the treatment of acute hepatitis C infection: North Chicago, Illinois Monday, May 25, 2026, 18:00 Hrs [IST] AbbVie, an ...
Novel triple-drug HCV combo achieves high SVR Direct-acting investigational "three-D" combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results